-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Pharmaceutical equipment is the "mother machine" of pharmaceutical production, and its downstream is mainly for traditional Chinese medicine (including Chinese herbal decoction pieces, Chinese patent medicine, etc.
), chemical drugs (chemical raw materials, chemical preparations, etc.
), biological drugs (including vaccines, blood products, etc.
) and several other segments of the pharmaceutical industry
.
Among them, biological drugs include genetic engineering drugs, antibody engineering drugs, blood products drugs, vaccines, diagnostic reagents, etc.
, which are new businesses that the pharmaceutical equipment industry has accelerated in recent years
.
Pharmaceutical equipment (Photo source: Pharmaceutical Network) In recent years, policies have been issued from the national level to the local level to support the development and growth of the biopharmaceutical industry, injecting impetus and vitality into the development of enterprises
.
At the national level, relevant departments have successively issued industrial policies such as the "14th Five-Year Plan for the Development of Biopharmaceutical Industry", "Measures for the Administration of the Lot Release of Biological Products (2020 Revised Edition)", and "The Drug Administration Law of the People's Republic of China".
, batch issuance, production and other aspects have pointed out the direction for the development of the biopharmaceutical industry
.
At the local level, for example, in view of the high technical requirements, difficult development, long R&D cycle and high cost of biological drug R&D, Yantai High-tech Zone makes good use of the new combined tax and fee support policy to provide enterprises with tax reduction and tax rebates.
” "Red envelopes" to inject "full vitality" into the biopharmaceutical industry; Baoshan District, Shanghai recently issued a major policy of "Biopharmaceutical 2.
0", which covers the entire field of life and health and the biopharmaceutical industry, from research and development, clinical, manufacturing, application.
All links in the entire production chain will further strengthen support
.
With the support of favorable policies, investment and financing in the field of biomedicine is also very hot
.
According to statistics, in the last week alone, there were 21 investment and financing events in the biomedical field, far exceeding other fields such as semiconductors and information technology
.
Among them, the recombinant antibody drug R&D outsourcing company "Baiying Bio" received about 500 million yuan in Series B financing, and the innovative antibody drug developer Banke Bio received over 10 million yuan in angel round financing
.
At the same time, biopharmaceutical companies are also intensively rushing to the capital market.
On September 1, Biositu landed on the main board of the Hong Kong Stock Exchange and became the first stock in gene editing, with a total market value approaching HK$10.
4 billion
.
On September 2, Opmax was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange and became the first cell culture medium in China, with a market value of over 10 billion that day
.
Opmax plans to raise 1.
6 billion yuan this time, which will be used for commercial production of CDMO biological drugs, cell culture R&D center projects and supplementary working capital
.
With the fierce competition in the biopharmaceutical industry, new technologies are also accelerating iterative upgrades.
Among them, the development of a new generation of biotechnologies represented by gene therapy, cell therapy, synthetic biotechnology, bifunctional antibodies, etc.
has gradually matured, bringing about changes in the pharmaceutical industry.
opportunity
.
In this context, many powerful domestic pharmaceutical companies have independently developed core technology platforms such as antibody display and screening platforms and antibody production platforms to enhance their competitiveness
.
Under the multiple resonances of favorable policies, capital overweight, and technological iteration, the entire biopharmaceutical industry has developed rapidly.
In the future, new products will continue to be launched, and the pace of capacity expansion of pharmaceutical companies will also accelerate.
It is expected that the industry's demand for high-end pharmaceutical equipment will also increase.
will continue to flourish
.
The industry predicts that by 2025, the biopharmaceutical market in China's biopharmaceutical field will exceed the 800 billion mark
.
The analysis believes that at present, the above factors are expected to promote the growth of the pharmaceutical equipment and consumables industry, and with the gradual expansion of domestic enterprises, it is expected to gradually promote the chromatography column system, disposable plastic consumables, etc.
by virtue of the advantages of high quality and low price.
The domestic substitution of high-end equipment and consumables has broken the bottleneck of "stuck neck" of foreign-funded enterprises
.
However, the industry also reminds that the key point is to observe the company's performance growth and the continuity of order growth.
If the order has a continuous growth trend, it can be extended from the short logic to the long logic
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
), chemical drugs (chemical raw materials, chemical preparations, etc.
), biological drugs (including vaccines, blood products, etc.
) and several other segments of the pharmaceutical industry
.
Among them, biological drugs include genetic engineering drugs, antibody engineering drugs, blood products drugs, vaccines, diagnostic reagents, etc.
, which are new businesses that the pharmaceutical equipment industry has accelerated in recent years
.
Pharmaceutical equipment (Photo source: Pharmaceutical Network) In recent years, policies have been issued from the national level to the local level to support the development and growth of the biopharmaceutical industry, injecting impetus and vitality into the development of enterprises
.
At the national level, relevant departments have successively issued industrial policies such as the "14th Five-Year Plan for the Development of Biopharmaceutical Industry", "Measures for the Administration of the Lot Release of Biological Products (2020 Revised Edition)", and "The Drug Administration Law of the People's Republic of China".
, batch issuance, production and other aspects have pointed out the direction for the development of the biopharmaceutical industry
.
At the local level, for example, in view of the high technical requirements, difficult development, long R&D cycle and high cost of biological drug R&D, Yantai High-tech Zone makes good use of the new combined tax and fee support policy to provide enterprises with tax reduction and tax rebates.
” "Red envelopes" to inject "full vitality" into the biopharmaceutical industry; Baoshan District, Shanghai recently issued a major policy of "Biopharmaceutical 2.
0", which covers the entire field of life and health and the biopharmaceutical industry, from research and development, clinical, manufacturing, application.
All links in the entire production chain will further strengthen support
.
With the support of favorable policies, investment and financing in the field of biomedicine is also very hot
.
According to statistics, in the last week alone, there were 21 investment and financing events in the biomedical field, far exceeding other fields such as semiconductors and information technology
.
Among them, the recombinant antibody drug R&D outsourcing company "Baiying Bio" received about 500 million yuan in Series B financing, and the innovative antibody drug developer Banke Bio received over 10 million yuan in angel round financing
.
At the same time, biopharmaceutical companies are also intensively rushing to the capital market.
On September 1, Biositu landed on the main board of the Hong Kong Stock Exchange and became the first stock in gene editing, with a total market value approaching HK$10.
4 billion
.
On September 2, Opmax was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange and became the first cell culture medium in China, with a market value of over 10 billion that day
.
Opmax plans to raise 1.
6 billion yuan this time, which will be used for commercial production of CDMO biological drugs, cell culture R&D center projects and supplementary working capital
.
With the fierce competition in the biopharmaceutical industry, new technologies are also accelerating iterative upgrades.
Among them, the development of a new generation of biotechnologies represented by gene therapy, cell therapy, synthetic biotechnology, bifunctional antibodies, etc.
has gradually matured, bringing about changes in the pharmaceutical industry.
opportunity
.
In this context, many powerful domestic pharmaceutical companies have independently developed core technology platforms such as antibody display and screening platforms and antibody production platforms to enhance their competitiveness
.
Under the multiple resonances of favorable policies, capital overweight, and technological iteration, the entire biopharmaceutical industry has developed rapidly.
In the future, new products will continue to be launched, and the pace of capacity expansion of pharmaceutical companies will also accelerate.
It is expected that the industry's demand for high-end pharmaceutical equipment will also increase.
will continue to flourish
.
The industry predicts that by 2025, the biopharmaceutical market in China's biopharmaceutical field will exceed the 800 billion mark
.
The analysis believes that at present, the above factors are expected to promote the growth of the pharmaceutical equipment and consumables industry, and with the gradual expansion of domestic enterprises, it is expected to gradually promote the chromatography column system, disposable plastic consumables, etc.
by virtue of the advantages of high quality and low price.
The domestic substitution of high-end equipment and consumables has broken the bottleneck of "stuck neck" of foreign-funded enterprises
.
However, the industry also reminds that the key point is to observe the company's performance growth and the continuity of order growth.
If the order has a continuous growth trend, it can be extended from the short logic to the long logic
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
